The US Rollout of MiniMed 780G With Abbott's Sensor May Lift MDT Stock

Core Insights - Medtronic plc has initiated the U.S. commercial rollout of the MiniMed 780G system integrated with Abbott's Instinct sensor, marking a significant advancement in diabetes management technology [1][8] - The MiniMed 780G system has received multiple regulatory approvals, including CE Mark for expanded indications and U.S. FDA approval for adults with type 2 diabetes, enhancing its market potential [2][4] - The global diabetes devices market is valued at $30.31 billion in 2023 and is expected to grow at a CAGR of 7.5% through 2030, driven by increasing diabetes prevalence and technological advancements [9] Company Developments - The MiniMed 780G system automatically adjusts insulin every five minutes based on real-time glucose readings, simplifying diabetes management [4][5] - The integration of Abbott's Instinct sensor, which features advanced continuous glucose monitoring technology, enhances the MiniMed 780G's capabilities [4][6] - Medtronic's Diabetes business is experiencing a strong innovation cycle, with recent product launches expanding its sensor portfolio [2][6] Financial Performance - Medtronic's market capitalization stands at $132.48 billion, with fiscal 2026 EPS expected to grow by 2.9% over 2025 [3] - The company reported worldwide revenues of $8.961 billion for fiscal 2026 second-quarter, reflecting a 6.6% year-over-year increase, with the Diabetes business growing particularly strong in international markets [10] - Year-to-date, Medtronic's shares have increased by 27.8%, outperforming the industry growth of 3.9% [11]